APG777 + APG990 for Atopic Dermatitis
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment combination, APG777 and APG990, for individuals with moderate-to-severe atopic dermatitis, a type of eczema that causes itchy and inflamed skin. The goal is to determine the safety and effectiveness of these medications compared to an existing treatment, dupilumab. Participants will be involved for about 82 weeks, including time for screening, treatment, and follow-up. This study may suit adults who have had atopic dermatitis for at least a year, with symptoms not well controlled by creams or ointments. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.
Will I have to stop taking my current medications?
The trial requires that you stop using any topical medications for atopic dermatitis 7 days before starting and any systemic treatments or therapies that could affect atopic dermatitis 4 weeks before starting. It's best to discuss your current medications with the study team to see if they are affected.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that APG990 is generally safe. One study found that it remains in the body for about 60 days and is well-tolerated, making it a promising treatment for atopic dermatitis. This suggests it might only need administration every 3-6 months, reducing the number of doses required.
For APG777, earlier trials showed positive results in patients with moderate-to-severe atopic dermatitis. Although specific safety details for APG777 alone weren't highlighted, its progression to later trials suggests it was well-tolerated in earlier studies.
The current trial examines the safety and tolerability of these two treatments when used together. Since this trial is in the early stages, it primarily focuses on how well participants handle taking both drugs simultaneously.12345Why are researchers excited about this trial's treatments?
Researchers are excited about the combination of APG777 and APG990 for atopic dermatitis because it brings a fresh approach to treatment. Unlike standard options like Dupilumab, which typically target immune pathways to reduce inflammation, this combination may offer a novel mechanism or pathway that directly alters the disease process. Such innovation could potentially provide enhanced efficacy or faster relief, giving hope to patients who haven't found success with existing therapies. By targeting different aspects of the condition, APG777 and APG990 could change the way we manage atopic dermatitis.
What evidence suggests that this trial's treatments could be effective for atopic dermatitis?
Research has shown that APG777 and APG990 may help treat moderate-to-severe atopic dermatitis (AD). In this trial, participants will receive a combination of these two treatments. A recent study demonstrated that APG777 achieved its main goals after 16 weeks, proving it can reduce symptoms. Early results for APG990, an antibody, also surpassed expectations, suggesting it might help manage AD. These findings indicate that using APG777 and APG990 together could potentially provide relief for people with AD.15678
Are You a Good Fit for This Trial?
Adults with moderate-to-severe atopic dermatitis can join this study. Participants will be involved for about 82 weeks, including screening, treatment, and follow-up periods. Specific eligibility details are not provided.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive the combination of APG777 + APG990 or dupilumab from Baseline to Week 24
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- APG777
- APG990
Find a Clinic Near You
Who Is Running the Clinical Trial?
Apogee Therapeutics, Inc.
Lead Sponsor